Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Paltech shows 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current patent activity involves the distinct examiner and the distinct art unit. JEAN P CORNET is the busiest examiner, with 1 busiest examiner pending action currently assigned.
The presence of the pending office action within the Biotechnology & Pharmaceuticals field indicates a specialized prosecution focus. Because the workload is handled by the distinct examiner, the applicant's strategy is tied to the specific review patterns of JEAN P CORNET. The busiest examiner pending action represents the full scope of the current USPTO engagement. Having the distinct art unit involved suggests that the underlying technology is highly specific and does not span multiple classification areas. For the applicant, this means that the outcome of the action will define the portfolio's short-term success. The reliance on a single point of contact at the office requires a precise understanding of the examiner's specific requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690384 | BIOACTIVE MOLECULES FOR USE IN TREATING INSULIN RESISTANCE AND/OR RESTORING GLUCOSE HOMEOSTASIS | CORNET, JEAN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18690384 | BIOACTIVE MOLECULES FOR USE IN TREATING INSULIN RESISTANCE AND/OR RESTORING GLUCOSE HOMEOSTASIS | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18690384 | BIOACTIVE MOLECULES FOR USE IN TREATING INSULIN RESISTANCE AND/OR RESTORING GLUCOSE HOMEOSTASIS | CORNET, JEAN P | 1628 | §103§112 | Non-Final OA | — | Pending | Mar 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial